Yeah, no one likes the idea of dilution, but I think they want this shelf registration in place so they can monitor market conditions. I'm anticipating NWBO will utilize the shelf at the appropriate time. They don't need the money right away.
Market cap is still only $220M. Results coming soon. What is DCVax-L alone is worth in GBM? DCVax is a platform that may work on ALL solid tumors, not just GBM, prostate and ovarian. DCVax-Direct results will be out soon for a slew of different inoperable tumors. What's that worth?
DCVax is a franchise vaccine, not just for one or a few indications. You know big pharma is watching and fears what this will do to their chemotherapies. I believe a hostile takeover attempt is likely to occur. Just wait for the first the strike, the rest will not just sit idly by and let that happen. Does NWBO have a poison pill provision? I sure do hope so.
It's currently still under $5. Catalysts coming soon (DCVax-L, DCVax-Direct), financing in place, media starting to show interest. Price still hasn't caught up with all the milestones. NWBO pipeline has never been in a better position than at this moment. Moving forward!
That's for sure. I didn't invest in NWBO for a measly $1.50 a share gain. I've got over 50000 shares that I'm holding for the long haul.
Listen to the IMUC cc from today. No way they are not going to go with PCT. They are not changing ship between p2 and p3. PCT is also anticipating an uptick in contracts as evidenced by the increase in manufacturing capacity about to come online.
This, of course, is assuming ICT-107 warrants a p3 which by most accounts looks likely.
New China H7N9 bird flu cases 'signal potential winter epidemic'
By Kate Kelland
LONDON (Reuters) - Fresh human cases in eastern China of a deadly new strain of bird flu signal the potential for "a new epidemic wave" of the disease in coming winter months, scientists said on Thursday.
The strain, known as H7N9, emerged for the first time in humans earlier this year and killed around 45 of the some 135 people it infected before appearing to peter out in China During the summer.
But a new case in October in a 35-year-old man from China's eastern Zhejiang province shows that the virus "has re-emerged in winter 2013" and "indicates a possible risk of a larger outbreak of H7N9 this winter," according to Chinese researchers writing in the online journal Euro surveillance.
Flu experts around the world have been warning that despite the marked drop off in cases during the summer months, the threat posed by H7N9 bird flu has not passed.
Bird Flu Found Outside Shanghai: Could It Come to …Play video."Bird Flu Found Outside Shanghai: Could It Come to …
Ab Osterhaus, a leading virologist based at the Erasmus Medical Center in the Netherlands who has been tracking the virus, told Reuters earlier this month: "We're bracing for what's going to happen next."
The first scientific analysis of probable transmission of the new flu from person to person, published in the British Medical Journal in August, gave the strongest proof yet that it can jump between people and so could potentially cause a human pandemic.
And another study published in August identified several other H7 flu viruses circulating in birds that "may pose threats beyond the current outbreak".
In a detailed analysis of the 35-year-old man's case, scientists from the Zhejiang Provincial Center for Disease Control and Prevention said it differed from previous ones in that it was a severe case in a younger patient "with no obvious underlying diseases and no obvious recent direct contact with live poultry"...
Yep, low volume so this is not a sell-off. Good to get shares on these dips. Holding long.
China reports first new case of H7N9 bird flu since August
BEIJING | Wed Oct 16, 2013 11:09am EDT
(Reuters) - China has confirmed a new human case of the deadly H7N9 strain of bird flu, the country's first report of an infection since August, the World Health Organization (WHO) said on Wednesday.
A 35-year-old man in Shaoxing in China's eastern province of Zhejiang has been hospitalized with the virus and is in critical condition, WHO said.
Zhejiang has recorded the highest number of H7N9 infections anywhere in China.
Some 45 people have died from H7N9 flu, which was unknown in humans until the first cases were detected in people early this year.
The Geneva-based WHO said that to date, it had been informed of a total 136 laboratory-confirmed human cases of H7N9 infection, including the 45 deaths.
Currently, three patients are hospitalized and 88 have been discharged, it said in a statement, adding that there was no evidence so far of sustainable human-to-human transmission.
While there has been only a handful of H7N9 infections during the summer months after a surge in April, flu experts warn that the threat posed by the virus has not passed.
The first scientific analysis of probable transfer of the new flu strain between humans, published in the British Medical Journal in August, gave the strongest proof yet that it can jump between people and so potentially cause a human pandemic.
Another study published in August identified several other H7 flu viruses circulating in birds that "may pose threats beyond the current outbreak".
(Reporting by Michael Martina in Beijing and Kate Kelland in London; Editing by Gareth Jones)
Yep, so did I. I now have almost 23000 shares at $6.47 average. Holding long. I still think that link with the Vatican is BS, but hey, if it's a good marketing ploy, then so be it.
I think that was the approval of the second draft. We're still waiting for the outcome of the Appraisal Committee meeting.
see guidance nice org uk/TAG/276
NICE has agreed that the Appraisal Committee will consider the new evidence on the cost effectiveness of PIXUVRI at its meeting on 11 September 2013.
Maybe a decision is already pending to approve Pixuvri in the U.K.
If they do it, they should do it fast to save them money. Not as good for ONTY longs, but that's why the timing works for Merk. ONTY holders will probably complain, but likely they will accept a serious offer. Seems like they already believe the drug is working. The did scour the START data afterall. Just keep holding, just keep holding...
If GSK really wanted to make an impact in DMD, they probably would wish to buy SRPT outright. Maybe 4 or 5 bil dollars? SRPT I hope would never agree and will do this alone. Heh, maybe partner with GSK in EU?
Just the tip of the iceberg. More upgrades once the dismal data from RNA unfolds like an ugly artichoke. Go ahead and short. Makes the surge up a lot sweeter if you're long, buying on the dips, and holding.